$BSX

Habiger David C purchased $100K of BSX

Habiger David C purchased 2,100 shares of BOSTON SCIENTIFIC CORP (BSX) at $47.59 on 2026-08-05.

Original reporting
SEC EDGAR · Habiger David C
Published Aug 7, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 8:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BSX
Neutral
low confidence
Mentioned
$BSX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BSXNeutralLow
01

Why it matters

The only disclosed new fact is the director’s open-market purchase details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may note insider buying as a mild sentiment input, but there is no accompanying fundamental or regulatory catalyst in the text.

03

What to watch

The Form 4 states no 10b5-1 plan, but the article provides no context on motivation, prior trading history, or whether the purchase size is meaningful versus typical director activity.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-07 after-hours; transaction dated 2026-08-05

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Boston Scientific.

Company-level read

Ticker impact

$BSXNeutralLow confidence
Context

SEC Form 4 shows director Habiger David C bought 2,100 shares of Boston Scientific at $47.5890 on 2026-08-05.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment.

Evidence & confidence

The filing is an insider buy, but it is not tied to new company guidance, contracts, litigation, or regulatory actions in the text.

Market effects

No sector read-through is provided beyond a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine (compensation, diversification, or pre-planned liquidity needs) and may not reflect a new bullish thesis.

Key entities

  • Boston Scientific Corp

    Subject of the Form 4 insider transaction disclosure.

  • Habiger David C

    Director who purchased 2,100 shares on 2026-08-05.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BSXMed

Boston Scientific (BSX) Names Joseph Fitzgerald COO, Restructure

Boston Scientific (BSX) appointed Joseph M. Fitzgerald as COO, effective January 1, 2027, and restructured operations into three segments. The company is valued at $42.19, with a GF Value™ of $107.35, indicating a 60.7% undervaluation. BSX has a GF Score™ of 79, reflecting strong financial health and growth prospects, despite net insider selling and mixed guru activity.

$BSXHigh

FDA Approves SpaceOAR Flex Hydrogel Rectal Spacer

FDA cleared Boston Scientific's SpaceOAR Flex Hydrogel, a rectal spacer for prostate cancer radiation therapy. The company claims it offers simpler setup and flexible delivery. Interim trial data showed 92.4% of patients had a 25% reduction in rectal radiation dose. Boston Scientific funded the study.

$BSXMedAI 8/10

Boston Scientific's MedSurg Diversification Bolsters Growth Prospects

Boston Scientific reported mixed Q2 2026 results, with Endoscopy sales up 7% YoY and Neuromodulation up 12%, but Urology underperforming. The company received FDA clearance for RIVOS and plans key launches to boost Urology growth. BSX shares fell 30.2% over six months, trading at a forward P/S ratio of 2.89. Medtronic and Teleflex also reported recent developments.